Visceral Pain - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Visceral Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Visceral Pain - Pipeline Review, H2 2016', provides an overview of the Visceral Pain pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Visceral Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Visceral Pain
- The report reviews pipeline therapeutics for Visceral Pain by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Visceral Pain therapeutics and enlists all their major and minor projects
- The report assesses Visceral Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Visceral Pain

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Visceral Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Visceral Pain Overview 7
Therapeutics Development 8
Pipeline Products for Visceral Pain - Overview 8
Pipeline Products for Visceral Pain - Comparative Analysis 9
Visceral Pain - Therapeutics under Development by Companies 10
Visceral Pain - Therapeutics under Investigation by Universities/Institutes 11
Visceral Pain - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Visceral Pain - Products under Development by Companies 14
Visceral Pain - Products under Investigation by Universities/Institutes 15
Visceral Pain - Companies Involved in Therapeutics Development 16
Addex Therapeutics Ltd 16
Astellas Pharma Inc. 17
Chromocell Corporation 18
GIcare Pharma Inc 19
Grunenthal GmbH 20
Medestea Research & Production S.p.A. 21
Neurim Pharmaceuticals Ltd 22
Pfizer Inc. 23
Visceral Pain - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 30
Drug Profiles 32
ADX-71441 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ADX-71743 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ASP-7663 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CC-8464 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
GIC-1002 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
MED-1101 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
NEO-5937 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
NeuP-12 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
piromelatine - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
PR-38 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
RO-656570 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
SBFI-26 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Synthetic Peptides to Activate OXTR for Oncology and Abdominal Pain - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
URB-937 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Visceral Pain - Dormant Projects 53
Visceral Pain - Discontinued Products 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Number of Products under Development for Visceral Pain, H2 2016 8
Number of Products under Development for Visceral Pain - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Visceral Pain - Pipeline by Addex Therapeutics Ltd, H2 2016 16
Visceral Pain - Pipeline by Astellas Pharma Inc., H2 2016 17
Visceral Pain - Pipeline by Chromocell Corporation, H2 2016 18
Visceral Pain - Pipeline by GIcare Pharma Inc, H2 2016 19
Visceral Pain - Pipeline by Grunenthal GmbH, H2 2016 20
Visceral Pain - Pipeline by Medestea Research & Production S.p.A., H2 2016 21
Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 22
Visceral Pain - Pipeline by Pfizer Inc., H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Visceral Pain - Dormant Projects, H2 2016 53
Visceral Pain - Dormant Projects (Contd..1), H2 2016 54
Visceral Pain - Dormant Projects (Contd..2), H2 2016 55
Visceral Pain - Discontinued Products, H2 2016 56